tiprankstipranks
Trending News
More News >
Intervacc AB (SE:IVACC)
:IVACC

Intervacc AB (IVACC) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Intervacc AB

(Frankfurt:IVACC)

Rating:44Neutral
Price Target:
kr1.00
▲(7.53%Upside)
Intervacc AB's stock score is primarily impacted by its weak financial performance and unattractive valuation. The lack of profitability and negative cash flows are significant risks, while bearish technical signals further contribute to the cautious outlook.

Intervacc AB (IVACC) vs. iShares MSCI Sweden ETF (EWD)

Intervacc AB Business Overview & Revenue Model

Company DescriptionIntervacc AB (IVACC) is a Swedish biotechnology company that specializes in the development of novel vaccines for animals. Operating primarily within the veterinary health sector, the company focuses on creating innovative solutions to combat infectious diseases affecting livestock and companion animals. Their core products include Strangvac, a vaccine developed to protect horses against strangles, a highly contagious equine disease.
How the Company Makes MoneyIntervacc AB generates revenue primarily through the sale and distribution of its veterinary vaccines. The company's main revenue stream comes from Strangvac, which is marketed and sold to veterinary clinics, horse owners, and equine organizations. Intervacc also engages in strategic partnerships and collaborations with veterinary pharmaceutical companies for the distribution and co-development of vaccines, further contributing to its earnings. Additionally, the company may receive funding and grants for its research and development efforts from governmental or industry sources, supporting its ongoing innovation and product development initiatives.

Intervacc AB Financial Statement Overview

Summary
Intervacc AB faces substantial financial challenges, including consistent net losses and negative cash flows. While the balance sheet is bolstered by strong equity and no debt, the negative profitability and cash flow trends present significant risks.
Income Statement
25
Negative
Intervacc AB's income statement reveals significant challenges. The company experienced a negative gross profit margin and substantial net losses in recent years, indicating difficulties in covering production costs and achieving profitability. Revenue growth has been inconsistent, with a significant decline in recent periods, which poses a risk to future financial stability.
Balance Sheet
60
Neutral
The balance sheet of Intervacc AB shows a strong equity base with no debt, indicating low financial leverage and reduced risk of insolvency. However, the decline in total assets over the years suggests a reduction in company resources. The high equity ratio is a positive sign of financial stability, though it is offset by diminishing assets.
Cash Flow
30
Negative
Intervacc AB's cash flow statements highlight ongoing operating cash flow deficits, which could strain liquidity. Despite the negative free cash flow, the absence of financial debt provides some relief. Nonetheless, the company needs to enhance its cash generation capabilities to sustain operations and fund growth.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue13.97M11.79M8.02M9.68M5.24M4.78M
Gross Profit-1.54M-3.53M-13.81M3.37M6.25M4.64M
EBITDA-54.32M-58.75M-68.98M-57.73M-23.15M-19.39M
Net Income-71.30M-75.52M-102.85M-64.16M-29.38M-25.60M
Balance Sheet
Total Assets363.31M187.32M259.61M265.04M329.39M355.28M
Cash, Cash Equivalents and Short-Term Investments216.09M34.40M88.34M45.70M115.71M164.25M
Total Debt97.00K145.00K181.00K322.00K433.00K383.00K
Total Liabilities20.75M24.99M21.68M14.88M21.14M17.67M
Stockholders Equity342.56M162.33M237.93M250.16M308.25M337.61M
Cash Flow
Free Cash Flow-49.19M-53.90M-47.94M-75.92M-48.67M-31.50M
Operating Cash Flow-48.58M-53.20M-45.83M-69.79M-25.46M-20.08M
Investing Cash Flow-614.00K-706.00K-2.11M-6.13M-23.13M-11.27M
Financing Cash Flow193.41M-36.00K90.58M5.91M50.00K143.06M

Intervacc AB Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.93
Price Trends
50DMA
1.05
Negative
100DMA
1.02
Negative
200DMA
1.44
Negative
Market Momentum
MACD
-0.02
Negative
RSI
49.72
Neutral
STOCH
61.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IVACC, the sentiment is Neutral. The current price of 0.93 is below the 20-day moving average (MA) of 0.97, below the 50-day MA of 1.05, and below the 200-day MA of 1.44, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 49.72 is Neutral, neither overbought nor oversold. The STOCH value of 61.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:IVACC.

Intervacc AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
kr421.36M-18.79%21.85%
51
Neutral
kr421.36M-18.79%21.85%
46
Neutral
C$194.90M-3.46-23.22%2.62%21.17%-0.58%
44
Neutral
€373.85M-47.73%45.52%93.35%
44
Neutral
€373.85M-47.73%45.52%93.35%
44
Neutral
€317.64M-24.61%56.48%40.18%
40
Neutral
kr367.60M
1.72%32.54%
40
Neutral
kr367.60M
1.72%32.54%
32
Underperform
€348.90M-205.65%24.25%
31
Underperform
kr323.69M-167.55%46.67%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:IVACC
Intervacc AB
0.99
-1.89
-65.65%
SE:ONCO
Oncopeptides AB
2.22
-0.30
-11.90%
SE:ONCO
Oncopeptides AB
2.22
-0.30
-11.90%
SE:CANTA
Cantargia AB
1.27
-2.83
-68.93%
SE:GUARD
Guard Therapeutics International AB
18.60
-9.98
-34.91%
SE:IMMU
Immunicum AB
8.12
-0.17
-2.05%
SE:IMMU
Immunicum AB
8.12
-0.17
-2.05%
SE:XBRANE
Xbrane Biopharma AB
0.24
0.02
11.85%
SE:XBRANE
Xbrane Biopharma AB
0.24
0.02
11.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025